Published in Cancer Immunol Immunother on January 01, 1985
Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci U S A (1990) 2.72
Tumor-elicited polymorphonuclear cells, in contrast to "normal" circulating polymorphonuclear cells, stimulate invasive and metastatic potentials of rat mammary adenocarcinoma cells. Proc Natl Acad Sci U S A (1989) 1.68
Apoptosis resistance and PKC signaling: distinguishing features of high and low metastatic cells. Neoplasia (2012) 0.81
Interactions between human monocytes and tumour cells. Monocytes can either enhance or inhibit the growth and survival of K562 cells. Br J Cancer (1992) 0.80
Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer (1975) 5.91
Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med (1981) 5.76
Natural cell-mediated immunity. Adv Cancer Res (1978) 5.53
Natural killer cells: their roles in defenses against disease. Science (1981) 4.59
Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer (1975) 3.54
Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J Immunol (1977) 3.52
Natural killer cells: characteristics and regulation of activity. Immunol Rev (1979) 3.14
Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol (1984) 3.07
Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. J Immunol (1981) 3.05
Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol (1979) 2.80
A functional comparison of human Fc-receptor-bearing lymphocytes active in natural cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol (1977) 2.60
Heterogeneity of natural killer cells. Annu Rev Immunol (1984) 2.59
Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med (1974) 2.40
Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic target cells. Int J Cancer (1977) 2.39
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med (2001) 2.37
Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med (1989) 2.33
Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: the Fisher scale revisited. Stroke (2001) 2.33
Natural killer (NK) cell activity in the rat. I. Isolation and characterization of the effector cells. J Immunol (1981) 2.12
Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest (1998) 2.06
Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol (1986) 2.05
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04
Low density of Thy 1 antigen on mouse effector cells mediating natural cytotoxicity against tumor cells. J Immunol (1978) 2.04
Immunosuppressive activity of a subline of the mouse EL-4 lymphoma. Evidence for minute virus of mice causing the inhibition. J Exp Med (1976) 2.01
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Depletion of monocytes from human peripheral blood mononuclear leukocytes: comparison of the sephadex G-10 column method with other commonly used techniques. J Immunol Methods (1980) 1.92
Cytotoxic reactivity of human lymphocytes cultured in vitro. J Immunol (1977) 1.88
Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res (1989) 1.84
Cytolytic and cytostatic activity on tumor cells of circulating human monocytes. Int J Cancer (1979) 1.84
T-cell homeostasis in HIV infection is neither failing nor blind: modified cell counts reflect an adaptive response of the host. Nat Med (1997) 1.82
Positive self regulation of cytotoxicity in human natural killer cells by production of interferon upon exposure to influenza and herpes viruses. J Exp Med (1982) 1.81
Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol (1983) 1.79
Chédiak-Higashi gene in humans I. Impairment of natural-killer function. J Exp Med (1980) 1.79
Mechanism of cytotoxicity by natural killer (NK) cells. Annu Rev Immunol (1986) 1.72
IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol (1999) 1.71
Breast conservation versus mastectomy: distress sequelae as a function of choice. J Clin Oncol (1989) 1.70
Inhibition of murine natural killer cell activity by prostaglandins. J Immunol (1980) 1.68
Cost and outcome of mechanical ventilation for life-threatening stroke. Stroke (2000) 1.67
Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. J Immunol (1975) 1.62
Cell-mediated immunity to tumor cells. Adv Cancer Res (1974) 1.60
In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur J Immunol (2000) 1.57
Mastectomy versus breast conservation surgery: mental health effects at long-term follow-up. Health Psychol (1992) 1.56
Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol (1985) 1.55
Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int J Cancer (1972) 1.55
Tumor necrosis factor in preterm and term labor. Am J Obstet Gynecol (1992) 1.53
Fc receptors on mouse effector cells mediating natural cytotoxicity against tumor cells. J Immunol (1977) 1.53
Two functionally distinct anti-tumor effector cells isolated from primary murine sarcoma virus-induced tumors. J Immunol (1976) 1.53
Natural killer (NK) cells and their possible roles in resistance against disease. Clin Immunol Rev (1981) 1.52
Clinical trial of an air-circulating cooling blanket for fever control in critically ill neurologic patients. Neurology (2001) 1.51
Cell-mediated cytotoxicity for bladder carcinoma: evaluation of a workshop. Cancer Res (1975) 1.51
Natural killer activity in the rat. II. Analysis of surface antigens on LGL by flow cytometry. J Immunol (1981) 1.51
Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer (1982) 1.50
Role of macrophages in the augementation of mouse natural killer cell activity by poly I:C and interferon. J Immunol (1979) 1.49
Identification and separation of Thy-1 positive mouse spleen cells active in natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity. J Immunol (1979) 1.48
Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol (1999) 1.48
Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res (1990) 1.45
Low affinity E-rosette formation by the human K cell. J Immunol (1978) 1.45
Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels. Cancer Immunol Immunother (1992) 1.45
Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer (1992) 1.45
Effect of antibody to theta antigen on cell-mediated immunity induced in syngeneic mice by murine sarcoma virus. J Natl Cancer Inst (1973) 1.45
Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods (1992) 1.44
Natural cytotoxicity of mouse monocytes and macrophages. J Immunol (1979) 1.43
Natural cell-mediated cytotoxicity in mice against non-lymphoid tumor cells and some normal cells. Int J Cancer (1977) 1.42
Gene amplification and gene dosage in cell lines derived from squamous cell carcinoma of the head and neck. Genes Chromosomes Cancer (1991) 1.42
Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer (1984) 1.42
Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver. J Exp Med (1984) 1.41
Effect of ultraviolet irradiation on MCA102 tumor cell immunogenicity and sensitivity to tumor necrosis factor. Cancer Res (1991) 1.41
Chédiak-Higashi gene in humans. II. The selectivity of the defect in natural-killer and antibody-dependent cell-mediated cytotoxicity function. J Exp Med (1980) 1.41
Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. Neurology (2002) 1.41
Inhibition of early murine hemopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-beta 1. J Immunol (1989) 1.39
Human T lymphocyte subpopulations: correlation between E-rosette-forming affinity and expression of the Fc receptor. J Immunol (1977) 1.39
Mediation of mouse natural cytotoxic activity by tumour necrosis factor. Nature (1986) 1.39
Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. J Immunol (1994) 1.39
Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. J Natl Cancer Inst (1995) 1.39
Isolation of human and rat natural killer cells. J Immunol Methods (1982) 1.39
Phospholipid methylation and phospholipase A2 activation in cytotoxicity by human natural killer cells. Proc Natl Acad Sci U S A (1981) 1.39
Natural cell-mediated cytotoxicity in rats. II. In vivo augmentation of NK-cell activity. Int J Cancer (1978) 1.38
Specificity of 51Cr-release cytotoxicity of lymphocytes immune to murine sarcoma virus. J Natl Cancer Inst (1974) 1.38
Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells. J Immunol (1986) 1.37
Natural cell-mediated cytotoxicity in rats. III. Effects of immunopharmacologic treatments on natural reactivity and on reactivity augmented by polyinosinic-polycytidylic acid. Int J Cancer (1978) 1.37
Destruction of human lymphoid tissue-culture cell lines by human peripheral lymphocytes in 51Cr-release cellular cytotoxicity assays. J Natl Cancer Inst (1974) 1.36
Specificity of natural cytotoxic reactivity of normal human lymphocytes against a myeloid leukemia cell line. J Natl Cancer Inst (1977) 1.36
Differential expression of H-2 gene products in tumour cells in associated with their metastatogenic properties. Nature (1980) 1.35
Analysis by a single cell cytotoxicity assay of natural killer (NK) cells frequencies among human large granular lymphocytes and of the effects of interferon on their activity. J Immunol (1982) 1.34
Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal (1990) 1.32
Cytotoxicity by cultured human lymphocytes: characteristics of effector cells and specificity of cytotoxicity. J Immunol (1979) 1.32
The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol (1995) 1.32
Wild-type gross leukemia virus: classification of soluble antigens (GSA). J Virol (1972) 1.31
An isotopic antiglobulin technique for measuring antibodies to cell-surface antigens. J Immunol (1969) 1.31
Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumour cells. Clin Exp Immunol (1971) 1.31
IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest (2001) 1.30
Natural cytotoxicity of mouse, rat, and human lymphocytes against heterologous target cells. J Natl Cancer Inst (1979) 1.30
Selective depletion of human natural killer cells on monolayers of target cells. J Immunol (1980) 1.29
Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst (1996) 1.29
Serological analysis of cell surface antigens of tumors induced by murine leukemia virus. J Natl Cancer Inst (1972) 1.29
Cutaneous hypersensitivity reactions to autologous extracts of malignant melanoma cells. Lancet (1970) 1.27
Rapid in vivo assay of mouse natural killer cell activity. J Natl Cancer Inst (1979) 1.26